Screener
BioCryst Pharmaceuticals BCRX Exercise of warrants
Exercise of warrants at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept bcrx:StockIssuedDuringPeriodValueExerciseOfWarrants.
The source filing: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 4:03 PM EST
- Fiscal year
- FY2025
- Accession
- 0001628280-26-012240
| Line item | Common Stock / Shares | Common Stock / Amount | Additional Paid-In Capital | Accumulated Other Comprehensive Income | Accumulated Deficit | Total Stockholders’Deficit |
|---|---|---|---|---|---|---|
| Vesting of restricted stock units | 1,276 | 13 | (13) | — | — | — |
| Shares withheld for taxes for vesting of restricted stock units | (59) | (1) | (369) | — | — | (370) |
| Employee stock purchase plan sales | 338 | 4 | 2,592 | — | — | 2,596 |
| Exercise of warrants | 14,997 | 150 | (150) | — | — | — |
| Issuance of shares to directors in lieu of cash retainer | 37 | — | 342 | — | — | 342 |
| Stock-based compensation expense | — | — | 55,615 | — | — | 55,615 |
| Balance at December 31, 2023 | 205,771 | $2,058 | $1,222,236 | $1,337 | $(1,681,159) | $(455,528) |
| Net loss | — | — | — | — | (88,881) | (88,881) |
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
FAQ
- What is BioCryst Pharmaceuticals's exercise of warrants?
- BioCryst Pharmaceuticals (BCRX) reported exercise of warrants of $0 in Q4 2023.
- What does exercise of warrants mean?
- The total value received from the exercise of warrants, representing the conversion of derivative instruments into common equity. This metric highlights potential capital inflows from warrant holders and the resulting impact on the company's total share count.
Ask your AI about BioCryst Pharmaceuticals's exercise of warrants.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude